Annual report for Sun Pharmaceutical Industries Ltd. for FY-2016
31-05-2016
Results Press Release for March 31, 2016
Sun Pharmaceutical Industries Ltd has informed BSE about : 1. Result Press Release for the period ended March 31, 2016.30-05-2016
Board recommends Dividend (Board Meeting on June 23, 2016 to consider Buy Back of equity shares)
Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2016, inter alia, has transacted the following:1. Recommended payment of dividend of Re. 1/- (Rupee One Only) per equity share of Re. 1/- each of the Company for the year ended March 31, 2016, subject to the approval of the members at the ensuing Annual General Meeting of the Company....30-05-2016
Announces Q4 & FY16 Results (Standalone & Consolidated) & Auditors Report (Standalone & Consolidated) for the period ended March 31, 2016
Sun Pharmaceutical Industries Ltd has announced the following results for the quarter & year ended March 31, 2016The Audited Standalone results for the Quarter ended March 31, 2016The Company has posted a net profit of Rs. 617.10 million for the quarter ended March 31, 2016 where as the same was at net loss of Rs. (793.40) million for the quarter ended March 31, 2015. Total Income is Rs. 22474.70 million for the quarter ended March...30-05-2016
Sun Pharma arms get US subpoena over drugs pricing
Sun Pharma, India's largest drug maker, has received a grand jury subpoena from the anti-trust division of the US Department of Justice seeking documents.30-05-2016
Intimation about receipt of a grand jury subpoena by the Company's US subsidiary
Sun Pharmaceutical Industries Ltd has informed BSE regarding "Intimation about receipt of a grand jury subpoena by the Company's US subsidiary".28-05-2016
Sun Pharma jumps 4% as subsidiary Taro reports healthy March quarter numbers
It is a sentiment booster for Sun Pharma. One can expect may be a 3-5 per cent uptick on the stock, Jani said. The stock rose 4.32 per cent to hit a high of Rs 813.75 on BSE.27-05-2016
Updates
Sun Pharmaceutical Industries Ltd has informed BSE that the Parties have terminated the Umbrella Agreement as well as the Transaction Agreements executed between Daiichi Sankyo Company Limited., Daiichi Sankyo (Thailand) Ltd. Ranbaxy, Ranbaxy (Netherlands) B.V., Ranbaxy UNICHEM Company Ltd., Ranbaxy (Thailand) Company Ltd. due to divestment of Ranbaxy by Daiichi Sankyo Company Limited....26-05-2016
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pratham Investments has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE25-05-2016
Zenotech to raise funds through rights issue to shareholders
NEW DELHI: Drug firm Zenotech Laboratories is looking to raise funds through a rights issue to its existing shareholders. The company's Board of Directors have considered and approved the "raising of funds by way of offer and issue of equity shares to the existing shareholders of the company on a rights basis", Zenotech Laboratories said in a filing to BSE. While it did not disclose the amount to be raised, the company said its board has constituted a committee of directors for the purpose. The committee has been authorised "to determine terms of the rights issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement, timing of the issue among others", it added. As per March 2016 shareholding pattern the promoter and promoter group hold 66.85 per cent shares in Zenotech Laboratories while public shareholding is at 33.15 per cent. Out of this Sun Pharmaceuticals Industries has 46.85 shares in the firm. Earlier in September 2015, Zenotech Laboratories had been registered as a sick firm with the Board for Industrial and Financial Reconstruction (BIFR). In a separate filing Zenotech Laboratories said its standalone net loss has narrowed to Rs 4.37 crore for the quarter ended March 31, 2016. It was Rs 10.20 crore for the corresponding period of the previous fiscal. Standalone net sales of the company stood at Rs 12.16 lakh for the quarter under consideration. It was Rs 89.12 lakh for the year ago period.21-05-2016